Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
Research output: Contribution to journal › Article
Adeno-associated virus (AAV) vectors are used to deliver potentially therapeutic genes in clinical trials in Parkinson's disease (PD). Pre-existing immunity to AAV and a local neuroinflammatory response might negatively affect the efficacy of such AAV-mediated gene delivery.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Journal||Journal of Gene Medicine|
|Publication status||Published - 2014|
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Clinical Memory Research Unit (013242610), Neuronal Survival (013212041)
No data available